Skip to search formSkip to main contentSkip to account menu

hexamethylene bisacetamide

Known as: N,N'-Hexamethylenebisacetamide, Acetamide, N,N'-hexamethylenebis-, HMBA 
A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

AcetamidesAntineoplastic AgentsHematinics
NCIt Antineoplastic Agent Terminology

Narrower (1)

NSC 95580

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1998
Review
1998
Teratocarcinomas and human embryology: Pluripotent human EC cell lines
The histogenesis of germ cell tumours (GCT) reflects the normal processes of gametogenesis, fertilisation and subsequent… 
Highly Cited
1991
Highly Cited
1991
Subtractive cDNA cloning using oligo(dT)30-latex and PCR: isolation of cDNA clones specific to undifferentiated human embryonal carcinoma cells.
The human embryonal carcinoma cell line NEC14 can be induced to differentiate by the addition of 10(-2)M N,N'-hexamethylene-bis… 
Highly Cited
1990
Highly Cited
1990
Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide.
The differentiation agent hexamethylene bisacetamide (HMBA) increased expression of transforming growth factor beta 1 (TGF beta 1… 
Highly Cited
1990
Highly Cited
1990
Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene
During chemically induced differentiation of Friend virus-infected mouse erythroleukemia (MEL) cell lines, there is a biphasic… 
Highly Cited
1988
Highly Cited
1988
Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid.
We have studied the expression of nine homeobox genes from Hox 1, Hox 2, Hox 3 and Hox 5 clusters in human embryonal carcinoma… 
Highly Cited
1987
Highly Cited
1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was tested in patients with refractory, solid tumors. Twenty… 
Highly Cited
1986
Highly Cited
1986
Replacement of 5-methylcytosine by cytosine: a possible mechanism for transient DNA demethylation during differentiation.
In an earlier study it was discovered that when Friend erythroleukemia cells (FELC) were exposed to a variety of chemical agents… 
Highly Cited
1986
Highly Cited
1986
Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
Hexamethylenebisacetamide (HMBA)-induced differentiation of murine erythroleukemia cells (MELC) is a multistep process involving… 
Highly Cited
1977
Highly Cited
1977
Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells.
Friend virus-transformed murine erythroleukemia cells express the program of erythropoietic differentiation under the influence… 
Highly Cited
1976
Highly Cited
1976
A new group of potent inducers of differentiation in murine erythroleukemia cells.
This report identifies a group of compounds, polymethylene bisacetamides (acetylated diamines), which are potent inducers of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)